Predicting late‐onset preeclampsia by detecting ELABELA content using an immunochromatographic colloidal gold test strip

Author:

Yang Na1,Liu Kangsheng2,Zhang Wenli1,Li Ying3,Shen Suqin2,Lu Chuanchuan4,Xu Kai1,Peng Wei5,Deng Cheng1,Chen Meilin6,Yang Lindong7,Lai Shanshan1ORCID

Affiliation:

1. School of Life Sciences Nanjing Normal University Nanjing China

2. Department of Clinical Laboratory Women's Hospital of Nanjing Medical University Nanjing Maternity and Child Health Care Hospital Nanjing China

3. Pan'an Mason Medical Technology Co., LTD. Jinhua China

4. Department of Obstetrics and Gynecology Women's Hospital of Nanjing Medical University Nanjing Maternity and Child Health Care Hospital Nanjing China

5. Guangzhou Key Laboratory for Clinical Rapid Diagnosis and Early Warning of Infectious Diseases KingMed School of Laboratory Medicine Guangzhou Medical University Guangzhou China

6. Pan'an County maternal and Child Health Hospital, Clinical Laboratory Jinhua China

7. Department of Obstetrics & Gynecology Affiliated Jinling Hospital Medical School of Nanjing University Nanjing China

Abstract

AbstractPreeclampsia is a pregnancy disorder that seriously affects the outcome of mothers and infants and lacks effective prediction and diagnosis methods. ELABELA is the second endogenous ligand of the apelin receptor (APJ) and is associated with the pathogenesis of preeclampsia. In a previous study, the authors found that the downregulation of ELABELA expression is closely related to late‐onset preeclampsia, which may be a marker for the clinical diagnosis of late‐onset preeclampsia. In this study, the authors again collected 120 maternal blood samples, including 60 pregnant women with a medical diagnosis of late‐onset preeclampsia. ELISA results showed that the serum ELABELA concentration in late‐onset preeclampsia pregnant women (12.57 ± 7.77 ng/mL) was significantly lower than that in normal pregnant women (36.99 ± 23.58 ng/mL), which was consistent with previously reported results. Therefore, the authors used an ELABELA monoclonal antibody to label four colloidal gold nanoparticles with different diameters (15, 30, 55, and 150 nm) and developed a transverse‐flow immunochromatographic band for the rapid and accurate detection of serum ELABELA levels. The strip test shows that colloidal gold with a diameter of 30 nm can be used as a good ELABELA detection marker and had more than 90% positive detection effect. Therefore, the authors hope that the colloidal gold strip with ELABELA as the diagnostic index developed by us will be popularized and applied in clinical diagnosis.

Funder

West China Hospital, Sichuan University

Priority Academic Program Development of Jiangsu Higher Education Institutions

China National Funds for Distinguished Young Scientists

National Key Research and Development Program of China

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3